Effects of Cannabidiol on Weight and Fasting Blood Sugar with Chronic and Subchronic Haloperidol Administration

Overview

Journal Discov Ment Health

Publisher Springer

Date 2023 Oct 20

PMID 37861864

Authors

Jaiyeola Abiola Kajero

Soraya Seedat

Jude U Ohaeri

Abidemi Akindele

Oluwagbemiga Aina

Affiliations

Soon will be listed here.

Abstract

Objectives: The duration of administration (e.g., subchronic or chronic) of haloperidol may influence its adverse effects. We studied the effects of duration of administration of haloperidol on body weight and fasting blood sugar (FBS). In addition, we examined whether orally administered cannabidiol (CBD) had any putative mitigating influence on haloperidol-induced body weight changes and FBS elevation.

Methods: Haloperidol (5 mg/kg/day) was administered for 21 days (subchronic administration), via the intraperitoneal (IP) route, or monthly (50 mg/kg monthly) for 3 months (chronic administration), via the intramuscular (IM) route, either alone or before CBD (5 mg/kg/day). Oral CBD (5 mg/kg/day) alone and distilled water alone were administered for 21 days. Weight and FBS were measured before administration of pharmacological agents (distilled water in the control group) and post-administration.

Results: Group differences in average weight across time were significant. Pairwise comparisons showed that mean weight of the subchronic (IP) haloperidol alone group (Group A) and the chronic (IM) haloperidol before CBD group (Group F) increased significantly over time. Post medications, there was a significant increase in mean FBS in the subchronic (IP) haloperidol group compared to the subchronic (IP) haloperidol before CBD group. There was also a significant reduction in mean FBS from the baseline for the control group only.

Conclusion: We demonstrated that the duration of administration of haloperidol influenced weight and FBS in rats, suggesting that metabolic side effects, may be influenced by duration of administration. CBD ameliorated the increase in weight and FBS observed in the subchronic (IP) haloperidol groups.

References

Campos A, Moreira F, Gomes F, Del Bel E, Guimaraes F . Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3364-78. PMC: 3481531. DOI: 10.1098/rstb.2011.0389. View

Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang G, Baker D . GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans. Diabetes Obes Metab. 2016; 18(12):1263-1273. DOI: 10.1111/dom.12780. View

Reynolds G, Kirk S . Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther. 2009; 125(1):169-79. DOI: 10.1016/j.pharmthera.2009.10.010. View

Andreassen O, Meshul C, Moore C, Jorgensen H . Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. Psychopharmacology (Berl). 2001; 157(1):11-9. DOI: 10.1007/s002130100767. View

Koller E, Cross J, Doraiswamy P, Malozowski S . Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy. 2003; 23(9):1123-30. DOI: 10.1592/phco.23.10.1123.32759. View

Seeman P . Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry. 2016; 6(10):e920. PMC: 5315552. DOI: 10.1038/tp.2016.195. View

Ishiguro H, Carpio O, Horiuchi Y, Shu A, Higuchi S, Schanz N . A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. Synapse. 2009; 64(1):92-6. DOI: 10.1002/syn.20714. View

Pratt W, Lin P, Pierce-Messick Z, Ilesanmi A, Clissold K . Contrasting effects of 5-HT receptor stimulation of the nucleus accumbens or ventral tegmentum on food intake in the rat. Behav Brain Res. 2017; 323:15-23. PMC: 5333165. DOI: 10.1016/j.bbr.2017.01.031. View

Bermudez-Silva F, Cardinal P, Cota D . The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol. 2011; 26(1):114-24. DOI: 10.1177/0269881111408458. View

10.

NAIDU P, Kulkarni S . Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol. 2002; 428(1):81-6. DOI: 10.1016/s0014-2999(01)01284-5. View

11.

Huestis M, Solimini R, Pichini S, Pacifici R, Carlier J, Busardo F . Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol. 2019; 17(10):974-989. PMC: 7052834. DOI: 10.2174/1570159X17666190603171901. View

12.

Pertwee R, Howlett A, Abood M, Alexander S, Di Marzo V, Elphick M . International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010; 62(4):588-631. PMC: 2993256. DOI: 10.1124/pr.110.003004. View

13.

Kapur S, Remington G . Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996; 153(4):466-76. DOI: 10.1176/ajp.153.4.466. View

14.

Ali M, Mirza L . Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment. AACE Clin Case Rep. 2021; 7(3):204-206. PMC: 8165126. DOI: 10.1016/j.aace.2021.01.004. View

15.

Balzan M, Cacciottolo J . Neuroleptic malignant syndrome presenting as hyperosmolar non-ketotic diabetic coma. Br J Psychiatry. 1992; 161:257-8. DOI: 10.1192/bjp.161.2.257. View

16.

Chaves Y, Genaro K, Stern C, de Oliveira Guaita G, de Souza Crippa J, Cunha J . Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes. Neurosci Lett. 2020; 729:135020. DOI: 10.1016/j.neulet.2020.135020. View

17.

Bishnoi M, Boparai R . An animal model to study the molecular basis of tardive dyskinesia. Methods Mol Biol. 2012; 829:193-201. DOI: 10.1007/978-1-61779-458-2_12. View

18.

Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S . Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One. 2009; 4(6):e5844. PMC: 2688760. DOI: 10.1371/journal.pone.0005844. View

19.

Britch S, Babalonis S, Walsh S . Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2020; 238(1):9-28. PMC: 7796924. DOI: 10.1007/s00213-020-05712-8. View

20.

Kajero J, Seedat S, Ohaeri J, Akindele A, Aina O . Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol. World J Biol Psychiatry. 2020; 21(8):612-626. DOI: 10.1080/15622975.2020.1752934. View